# Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes

> **NCT04979975** · PHASE2 · NOT_YET_RECRUITING · sponsor: **UBP Greater China (Shanghai) Co., Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Recurrent Genital Herpes

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** UB-621 low-dose
- **BIOLOGICAL:** UB-621 high-dose

## Key facts

- **NCT ID:** NCT04979975
- **Lead sponsor:** UBP Greater China (Shanghai) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04979975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04979975, "Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04979975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*